Attributes
UniProt ID
Protein Name
deleted
Ligand Name
CHLORIDE ION
DrugBank ID
None
PDB Ligand Accession
ChEMBL ID
n/a
PubChem ID
n/a
InChIKey
VEXZGXHMUGYJMC-UHFFFAOYSA-M
SMILES
[Cl-]
Drug Action
No data available
Affinity Metrics
No affinity data available
3D Structure
Interactive Mol* view for the current protein-molecule pair.
Structure: 3QWN
Hover over the Mol* viewer to rotate or zoom with the mouse. Move the cursor out of the viewer to go back to normal page scrolling and one-click navigation.
Hover inside the viewer to rotate or zoom. Move out to scroll the page or click links normally.
Color Legend
Unassigned regionsLigand / hetero atomse3qwnA3e3qwnA4e3qwnB1e3qwnB2e3qwnC3e3qwnC4e3qwnD3e3qwnD4e3qwnE3e3qwnE4e3qwnF3e3qwnF4e3qwnG1e3qwnG2e3qwnH1e3qwnH2e3qwnI3e3qwnI4e3qwnJ1e3qwnJ2e3qwnK3e3qwnK4e3qwnL3e3qwnL4
ECOD domains from experimental PDB structures interacting with ligand CL
| UniProt | DrugBank | PDB Ligand | PDB ID | ECOD Domain | Range Definition |
|---|---|---|---|---|---|
| A5ZK25 | n/a | CL | 3qwn | e3qwnA3 | A:101-233 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnA4 | A:28-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnB2 | B:23-101 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnC3 | C:101-233 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnC4 | C:31-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnD4 | D:30-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnE4 | E:29-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnF3 | F:101-233 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnF4 | F:29-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnG1 | G:102-228 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnG2 | G:23-101 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnH1 | H:101-227 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnH2 | H:0-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnI3 | I:101-233 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnI4 | I:29-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnJ1 | J:103-229 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnJ2 | J:24-102 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnK3 | K:101-233 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnK4 | K:28-100 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnL3 | L:101-233 |
| A5ZK25 | n/a | CL | 3qwn | e3qwnL4 | L:31-100 |